Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NARINDER SAINI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1356420665
CMS profile
1142372
Location
SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$12.83

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $12.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alkermes, Inc. $12.83 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NARINDER SAINI

NPI 1356420665 · CMS profile ID 1142372

Allopathic & Osteopathic Physicians / Internal Medicine

SPRINGFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NARINDER SAINI, NPI 1356420665, CMS profile ID 1142372, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356420665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $12.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $12.8304/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686626397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.83 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $9,450.00 1
PY2024 Principal investigator $23,855.10 5
PY2023 Recipient $11,082.59 1
PY2023 Principal investigator $9,599.85 7
PY2022 Recipient $3,897.05 1
PY2022 Principal investigator $1,244,253.27 83
PY2021 Recipient $434,945.60 1
PY2021 Principal investigator $917,788.30 69
PY2020 Recipient $15,112.10 3
PY2020 Principal investigator $408,488.40 195
PY2019 Recipient $586.07 1
PY2019 Principal investigator $552,873.53 77

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Allergan Inc. $586.07 12/31/2019 Covered Recipient Physician Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670008769
Principal investigator 1 Allergan Inc. $22,462.92 12/31/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670120505
Principal investigator 1 Allergan Inc. $1,130.63 12/31/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670124699
Principal investigator 1 Allergan Inc. $5,905.94 12/31/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670124887
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,400.00 12/19/2019 Non-covered Recipient Entity
Urgent Care Specialists, LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis No dispute reported 06/30/2026 696912855
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670115643
Principal investigator 1 Allergan Inc. $20,254.00 12/16/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670111553
Principal investigator 1 Allergan Inc. $6,868.50 12/11/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670108489
Principal investigator 1 Allergan Inc. $686.00 12/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670107175
Principal investigator 1 Allergan Inc. $700.00 12/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS DG No dispute reported 06/30/2026 670106395
Principal investigator 1 Allergan Inc. $383.63 12/05/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670106757
Principal investigator 1 Allergan Inc. $366.13 12/05/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670106765
Principal investigator 2 Ironwood Pharmaceuticals, Inc $3,550.50 12/03/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396477
Principal investigator 1 Ironwood Pharmaceuticals, Inc $6,952.50 12/03/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396479
Principal investigator 3 Ironwood Pharmaceuticals, Inc $68.00 12/03/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396481
Principal investigator 1 Allergan Inc. $7,200.00 12/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670104645
Principal investigator 1 Allergan Inc. $1,500.00 12/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670104653
Principal investigator 1 Allergan Inc. $8,000.00 12/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670104665
Principal investigator 1 Allergan Inc. $2,000.00 12/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670104669
Principal investigator 1 Allergan Inc. $400.00 12/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670104693
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670099337
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100427
Principal investigator 1 Allergan Inc. $955.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100479
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100893
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670101221
Principal investigator 1 Allergan Inc. $2,584.00 11/19/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670102695
Principal investigator 1 Allergan Inc. $1,276.80 11/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670098651
Principal investigator 1 Ironwood Pharmaceuticals, Inc $3,550.50 11/05/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705397229
Principal investigator 1 Ironwood Pharmaceuticals, Inc $5,098.50 11/05/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705397231
Principal investigator 1 Allergan Inc. $6.59 11/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670093839
Principal investigator 1 Ironwood Pharmaceuticals, Inc $2,500.00 10/29/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705399587
Principal investigator 1 Allergan Inc. $6,526.50 10/28/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670091783
Principal investigator 1 Allergan Inc. $31.04 10/25/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670091723
Principal investigator 1 Allergan Inc. $2,850.00 10/23/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670090099
Principal investigator 1 Allergan Inc. $2,400.00 10/14/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670084469
Principal investigator 3 Ironwood Pharmaceuticals, Inc $136.00 10/08/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396465
Principal investigator 1 Ironwood Pharmaceuticals, Inc $150.00 10/08/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396467
Principal investigator 2 Ironwood Pharmaceuticals, Inc $1,797.00 10/08/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396469
Principal investigator 3 Ironwood Pharmaceuticals, Inc $1,797.00 10/08/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396471
Principal investigator 2 Ironwood Pharmaceuticals, Inc $1,797.00 10/08/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MCP-103-205 No dispute reported 06/30/2026 705396473
Principal investigator 1 Allergan Inc. $22.53 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081225
Principal investigator 1 Allergan Inc. $33.82 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081229
Principal investigator 1 Allergan Inc. $11.29 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081233
Principal investigator 1 Allergan Inc. $11.29 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081237
Principal investigator 1 Allergan Inc. $325.00 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081241
Principal investigator 1 Allergan Inc. $4,800.00 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081495
Principal investigator 1 Allergan Inc. $2,400.00 10/01/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670081497
Principal investigator 1 Allergan Inc. $3,809.50 09/20/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670078549
Principal investigator 1 Allergan Inc. $3,491.25 09/19/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670078067
Principal investigator 1 Allergan Inc. $12,597.00 09/18/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670076251
Principal investigator 1 Allergan Inc. $16,473.00 08/30/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670070949
Principal investigator 1 Allergan Inc. $1,615.00 08/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670066133
Principal investigator 1 Allergan Inc. $2,413.00 08/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670066353
Principal investigator 1 Ironwood Pharmaceuticals, Inc $3,660.00 08/01/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705396453
Principal investigator 1 Ironwood Pharmaceuticals, Inc $68.00 08/01/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705396455
Principal investigator 1 Ironwood Pharmaceuticals, Inc $68.00 08/01/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705396457
Principal investigator 1 Allergan Inc. $1,225.50 07/16/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670058052
Principal investigator 1 Ironwood Pharmaceuticals, Inc $3,660.00 07/16/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397217
Principal investigator 1 Ironwood Pharmaceuticals, Inc $3,660.00 07/16/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397219
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,195.20 07/09/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397221
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,998.00 07/09/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397223
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,195.20 07/09/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397225
Principal investigator 2 Ironwood Pharmaceuticals, Inc $1,998.00 07/09/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE & RSCH
MD-7246_MCP103-205 No dispute reported 06/30/2026 705397227
Principal investigator 1 Allergan Inc. $6,517.00 06/18/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670052173
Principal investigator 1 Romark Laboratories, LC $121,329.85 06/07/2019 Non-covered Recipient Entity
Hometown Urgent Care & Research
A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza No dispute reported 06/30/2026 687330771
Principal investigator 1 Romark Laboratories, LC $201,001.21 06/07/2019 Non-covered Recipient Entity
Hometown Urgent Care & Research
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection No dispute reported 06/30/2026 687330781
Principal investigator 1 Allergan Inc. $5,519.50 05/22/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670047443
Principal investigator 1 Allergan Inc. $8,000.00 05/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670045387
Principal investigator 1 Allergan Inc. $2,000.00 05/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG No dispute reported 06/30/2026 670045391
Principal investigator 1 Allergan Inc. $6.85 04/23/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670040230
Principal investigator 1 Allergan Inc. $11.29 04/23/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670040277
Principal investigator 1 Allergan Inc. $3,686.00 04/16/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670038009
Principal investigator 1 Allergan Inc. $3,477.00 04/15/2019 Non-covered Recipient Entity
URGENT CARE SPECIALISTS LLC DBA HOMETOWN URGENTCA
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670037617
Principal investigator 1 Allergan Inc. $11.29 03/26/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670034169
Principal investigator 1 Allergan Inc. $6.70 03/26/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670034787
Principal investigator 1 Allergan Inc. $11.29 03/19/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670031999
Principal investigator 1 Allergan Inc. $11.29 02/12/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670024031
Principal investigator 1 Allergan Inc. $2,109.00 01/15/2019 Non-covered Recipient Entity
HOMETOWN URGENT CARE
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670016644